Cai Zhaoyi, Luo Qiang, Zhang Yuqun, Meng Rui, Tian Ming
The First College of Clinical Medical Science, China Three Gorges University, 183 Yiling Avenue, Yichang, 443003, China.
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Discov Oncol. 2025 May 30;16(1):965. doi: 10.1007/s12672-025-02797-5.
Protein kinase CK2 is known to have potent biological effects, and its high expression is closely associated with malignant phenotypes of tumors, especially hematological malignancies. Targeting protein kinase CK2 is a promising therapeutic direction in hematological malignancies, as it promotes the survival of tumor cells and regulates the cell cycle and enhances the resistance of tumor cells to tumor therapy. In recent years, a large number of studies have confirmed the therapeutic effect of targeting protein kinase CK2 in combination with other therapies in the treatment of hematological malignancies. Here, we reviewed the key signaling pathways regulated by protein kinase CK2, the role of protein kinase CK2 in various hematological malignant tumors, the research progress and the potential clinical application prospects.
已知蛋白激酶CK2具有强大的生物学效应，其高表达与肿瘤尤其是血液系统恶性肿瘤的恶性表型密切相关。靶向蛋白激酶CK2是血液系统恶性肿瘤中一个有前景的治疗方向，因为它促进肿瘤细胞存活、调节细胞周期并增强肿瘤细胞对肿瘤治疗的抗性。近年来，大量研究证实了靶向蛋白激酶CK2联合其他疗法在治疗血液系统恶性肿瘤方面的疗效。在此，我们综述了蛋白激酶CK2调控的关键信号通路、蛋白激酶CK2在各种血液系统恶性肿瘤中的作用、研究进展以及潜在的临床应用前景。
